GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocure Technology Inc (XCNQ:CURE) » Definitions » Shiller PE Ratio

Biocure Technology (XCNQ:CURE) Shiller PE Ratio : (As of May. 11, 2025)


View and export this data going back to 2010. Start your Free Trial

What is Biocure Technology Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Biocure Technology Shiller PE Ratio Historical Data

The historical data trend for Biocure Technology's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocure Technology Shiller PE Ratio Chart

Biocure Technology Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Biocure Technology Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biocure Technology's Shiller PE Ratio

For the Biotechnology subindustry, Biocure Technology's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocure Technology's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocure Technology's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Biocure Technology's Shiller PE Ratio falls into.


;
;

Biocure Technology Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Biocure Technology's E10 for the quarter that ended in Sep. 2024 is calculated as:

For example, Biocure Technology's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.001/127.2847*127.2847
=-0.001

Current CPI (Sep. 2024) = 127.2847.

Biocure Technology Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 -0.004 98.367 -0.005
201503 -0.005 99.789 -0.006
201506 -0.004 100.500 -0.005
201509 -0.004 100.421 -0.005
201512 -0.008 99.947 -0.010
201603 -0.001 101.054 -0.001
201606 -0.003 102.002 -0.004
201609 -0.009 101.765 -0.011
201612 0.000 101.449 0.000
201703 0.000 102.634 0.000
201706 -0.005 103.029 -0.006
201709 -0.095 103.345 -0.117
201712 -0.308 103.345 -0.379
201803 -0.096 105.004 -0.116
201806 -0.360 105.557 -0.434
201809 -0.090 105.636 -0.108
201812 -0.090 105.399 -0.109
201903 -0.090 106.979 -0.107
201906 -0.180 107.690 -0.213
201909 -0.090 107.611 -0.106
201912 -0.180 107.769 -0.213
202003 -0.090 107.927 -0.106
202006 -0.090 108.401 -0.106
202009 -0.090 108.164 -0.106
202012 -0.090 108.559 -0.106
202103 -0.090 110.298 -0.104
202106 -0.180 111.720 -0.205
202109 -0.090 112.905 -0.101
202112 0.270 113.774 0.302
202203 -0.026 117.646 -0.028
202206 -0.023 120.806 -0.024
202209 -0.024 120.648 -0.025
202212 0.000 120.964 0.000
202303 -0.026 122.702 -0.027
202306 0.270 124.203 0.277
202309 -0.011 125.230 -0.011
202312 -0.360 125.072 -0.366
202403 -0.002 126.258 -0.002
202406 -0.002 127.522 -0.002
202409 -0.001 127.285 -0.001

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biocure Technology  (XCNQ:CURE) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Biocure Technology Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Biocure Technology's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocure Technology Business Description

Traded in Other Exchanges
Address
1055 West Hastings Street, Suite 300, Vancouver, BC, CAN, V6E 2E9
Biocure Technology Inc is a South Korean-based Bio-Pharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. It Developing Biosimilars and CAR-T Cell pharmaceuticals. Its products are CAR-T Cell Therapy, Interferon Beta, Ranibizumab, and PEG-Filgrastim.
Executives
Konstantin Lichtenwald Director, Senior Officer

Biocure Technology Headlines